Biomea Fusion Stock (NASDAQ:BMEA)

Forecast Ownership Financials Chart

Previous Close

$1.93

52W Range

$0.87 - $2.99

50D Avg

$1.42

200D Avg

$1.38

Market Cap

$133.39M

Avg Vol (3M)

$1.18M

Beta

-0.30

Div Yield

BMEA Company Profile

Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral drugs to treat patients with diabetes and obesity. It’s lead clinical program’s drug candidates are COVALENT-111 and COVALENT-112, which has completed Phase II clinical trials of icovamenib for the treatment of Type 1 and Type 2 diabetes; COVALENT-211, which is in Phase II clinical trial of icovamenib for treating insulin-deficient type 2 diabetes; and COVALENT-212, which is in Phase II clinical trial of icovamenib for the treatment of type 2 diabetes. The company is also developing BMF-650, which is in Phase I glucagon-like peptide-131 clinical trial for the treatment of obesity. The company was incorporated in 2017 and is headquartered in San Carlos, California.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

Country

Employees

IPO Date

Apr 16, 2021

Website

BMEA Performance

BMEA Financial Summary

	Dec 25	Dec 24	Dec 23
Revenue	-	-	-
Operating Income	$-81.31M	$-144.07M	$-126.14M
Net Income	$-61.80M	$-138.43M	$-117.25M
EBITDA	$-83.51M	$-142.32M	$-124.62M
Basic EPS	$-1.18	$-3.83	$-3.44
Diluted EPS	$-1.18	$-3.83	$-3.44

Fiscal year ends in Dec 25 | Currency in USD

Peer Comparison

Ticker	Company
IMUX	Immunic, Inc.
ALXO	ALX Oncology Holdings Inc.
PMVP	PMV Pharmaceuticals, Inc.
CAMP	CAMP4 Therapeutics Corporation
CBUS	Cibus, Inc.
UNCY	Unicycive Therapeutics, Inc.
STRO	Sutro Biopharma, Inc.
GUTS	Fractyl Health, Inc.
RPTX	Repare Therapeutics Inc.